First American Trust FSB Has $25.59 Million Position in Eli Lilly and Company (NYSE:LLY)

Key Points

• First American Trust FSB increased its holdings in Eli Lilly by 6.4% during Q1, owning nearly 31,000 shares valued at approximately $25.6 million.
• Despite mixed ratings from analysts, the stock's consensus rating stands at "Moderate Buy" with an average target price of $984.41.
• Eli Lilly announced a $1.50 quarterly dividend on August 15th, resulting in a 1.0% annual yield and a payout ratio of 48.82%.

First American Trust FSB grew its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,986 shares of the company's stock after purchasing an additional 1,856 shares during the period. Eli Lilly and Company comprises about 2.4% of First American Trust FSB's holdings, making the stock its 6th largest position. First American Trust FSB's holdings in Eli Lilly and Company were worth $25,594,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of LLY. SouthState Corp increased its holdings in shares of Eli Lilly and Company by 8.5% during the 1st quarter. SouthState Corp now owns 11,321 shares of the company's stock valued at $9,350,000 after acquiring an additional 891 shares during the last quarter. Northeast Financial Group Inc. grew its holdings in Eli Lilly and Company by 3.1% in the 1st quarter. Northeast Financial Group Inc. now owns 637 shares of the company's stock valued at $526,000 after buying an additional 19 shares during the last quarter. Nuveen LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $4,613,912,000. Advent Capital Management DE bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $2,891,000. Finally, Cooper Financial Group lifted its position in shares of Eli Lilly and Company by 12.1% in the 1st quarter. Cooper Financial Group now owns 2,976 shares of the company's stock worth $2,458,000 after acquiring an additional 321 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of the business's stock in a transaction on Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 0.14% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. UBS Group cut their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday. Leerink Partners reissued a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $984.41.

Eli Lilly and Company Stock Performance

NYSE LLY traded down $15.71 during trading on Friday, reaching $625.15. 14,089,857 shares of the company's stock were exchanged, compared to its average volume of 5,397,104. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $972.53. The business has a 50 day moving average price of $774.10 and a 200-day moving average price of $799.34. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock has a market capitalization of $591.68 billion, a P/E ratio of 40.86, a PEG ratio of 0.87 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. The firm's revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.92 earnings per share. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 1.0%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.